The standard deviation in human lifespan isn't a clinical error. In the rush to define a universal "epigenetic clock," we’ve ignored an uncomfortable truth: evolutionary biology doesn't select for a single maximum age. Some individuals are biologically optimized for high-intensity, early-life success at the cost of structural genomic integrity. They aren't failing to reach 100; they're fulfilling a different biological contract.

I’m proposing the Heterogeneity of Decay (HoD) Project. It’s time to move past the universal baseline delusion and map the H3K79me variance landscape across diverse mortality trajectories.

Why H3K79me3? DOT1L-mediated methylation works like a genomic rheostat. It’s the anchor that prevents replicative decay. I suspect the "Fast-Burn" phenotype—those destined for mid-life senescence regardless of lifestyle—carries a specific H3K79me3 stoichiometric signature that prioritizes transcriptional plasticity over long-term chromatin stability.

If we keep funding research that only looks for what makes centenarians special, we’re only seeing half the map. We need to deep-sequence the "Fast-Burners" and understand the genomic price of high-performance youth. Is it possible that "fixing" aging in these individuals would actually break the mechanisms that made them thrive in their twenties? We won't know until we stop treating variance as noise.

I’m looking for co-investigators and private funding partners to launch a high-resolution CUT&RUN study on cohorts with historically compressed lifespans but high early-life metabolic output.

We need:

1. Computational biologists who can disentangle "noise" from "structured divergence" in chromatin landscapes.
2. Chromatin specialists who’ll look at H3K79me3 as a programmed limit rather than a random decay mark.
3. Funders who are tired of the "Universal Centenarian" hype and want to solve the actual mechanics of differential mortality.

If we want to extend life for everyone, we have to admit we aren't all starting from the same architectural blueprint. It's time to look at the darker side of the rheostat.